227 related articles for article (PubMed ID: 26387812)
1. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Diekstra MH; Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur J Clin Pharmacol; 2015 Dec; 71(12):1477-84. PubMed ID: 26387812
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
5. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
[TBL] [Abstract][Full Text] [Related]
6. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
[TBL] [Abstract][Full Text] [Related]
8. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
[TBL] [Abstract][Full Text] [Related]
13. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.
Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Oncotarget; 2017 Jan; 8(1):1204-1212. PubMed ID: 27901483
[TBL] [Abstract][Full Text] [Related]
16. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
18. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; de la Taille A; Tourani JM; Bigot P; Linassier C; Négrier S; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Br J Cancer; 2013 Mar; 108(4):887-900. PubMed ID: 23462807
[TBL] [Abstract][Full Text] [Related]
19. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
20. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]